Sponsors (6)
The bill substantially strengthens U.S. influenza preparedness—by funding R&D, accelerating vaccines/tests, and hardening supply chains—while imposing significant recurring federal costs and raising risks around funding tradeoffs, oversight, implementation, and public trust.
Hospitals, public-health agencies, and researchers receive sustained, sizable funding and budget authority to support vaccine R&D, stockpiles, and preparedness programs, enabling multi-year planning and operational readiness.
People at higher risk (older adults, people with chronic conditions) and the general public could get vaccine protection sooner and more reliably because the bill accelerates pandemic-capable vaccine availability (goal: first doses within 12 weeks) and invests in development of a universal influenza vaccine.
Public and private laboratories, clinicians, and patients gain expanded and faster diagnostic capacity (including support for pathogen-agnostic, automated tests and shortened assay timelines), improving early detection and response in a pandemic.
Taxpayers and federal budgets face large, recurring costs because the bill authorizes hundreds of millions to over a billion dollars annually for preparedness, increasing federal spending pressure and potential tradeoffs.
HHS/BARDA and other federal agencies may need to reallocate resources toward influenza countermeasures, potentially diverting funding and attention from other public‑health priorities or diseases.
Designating a 'health defense operations' bypass budget and concentrating funds in an executive-submitted category could reduce Congress's regular appropriations oversight and shift transparency/accountability dynamics.
Based on analysis of 6 sections of legislative text.
Directs HHS and partners to accelerate domestic influenza vaccine/diagnostic/therapeutic capacity, fund R&D and outreach, and create a recurring appropriations and new "health defense operations" budget category beginning FY2027.
Official title: To protect against seasonal and pandemic influenza, and for other purposes.
Introduced April 22, 2026 by Richard Ray Larsen · Last progress April 22, 2026
Creates a multiyear federal program to strengthen U.S. influenza preparedness by accelerating domestic vaccine and medical countermeasure production, expanding diagnostics and therapeutics development, improving public communication and vaccine confidence, and providing recurring funding and a new "health defense operations" budget category. It directs HHS, ASPR, BARDA, NIH, CDC, FDA and other agencies to publish implementation plans, form public–private partnerships, run demonstration communications projects, and submit annual reports and a specialized budget submission to the President; it also authorizes specified annual appropriations beginning FY2027 and $335 million/year for certain BARDA/ASPR influenza activities for FY2027–2031.